These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8988465)

  • 1. Pharmacology and neuroprotective properties of rasagiline.
    Finberg JP; Lamensdorf I; Commissiong JW; Youdim MB
    J Neural Transm Suppl; 1996; 48():95-101. PubMed ID: 8988465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.
    Finberg JP; Takeshima T; Johnston JM; Commissiong JW
    Neuroreport; 1998 Mar; 9(4):703-7. PubMed ID: 9559942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
    Miklya I
    Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.
    Finberg JP; Wang J; Bankiewicz K; Harvey-White J; Kopin IJ; Goldstein DS
    J Neural Transm Suppl; 1998; 52():279-85. PubMed ID: 9564628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.
    Goggi J; Theofilopoulos S; Riaz SS; Jauniaux E; Stern GM; Bradford HF
    Neuroreport; 2000 Dec; 11(18):3937-41. PubMed ID: 11192605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
    Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
    Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective monoamine oxidase subtype inhibition and striatal extracellular dopamine in the guinea-pig.
    Ilani T; Lamensdorf I; Finberg JP
    Br J Pharmacol; 2000 Aug; 130(8):1992-8. PubMed ID: 10952692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
    Youdim MB; Gross A; Finberg JP
    Br J Pharmacol; 2001 Jan; 132(2):500-6. PubMed ID: 11159700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.
    Youdim MB; Wadia A; Tatton W; Weinstock M
    Ann N Y Acad Sci; 2001 Jun; 939():450-8. PubMed ID: 11462801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
    Sagi Y; Weinstock M; Youdim MB
    J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
    Chen JJ; Ly AV
    Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
    Blandini F; Armentero MT; Fancellu R; Blaugrund E; Nappi G
    Exp Neurol; 2004 Jun; 187(2):455-9. PubMed ID: 15144871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
    Chen JJ; Swope DM
    J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease.
    Ledreux A; Boger HA; Hinson VK; Cantwell K; Granholm AC
    Brain Res; 2016 Jan; 1631():34-45. PubMed ID: 26607251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
    Vaglini F; Pardini C; Cavalletti M; Maggio R; Corsini GU
    Brain Res; 1996 Nov; 741(1-2):68-74. PubMed ID: 9001706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.